Despite Performance Declines Since Spinning Out of 3M, Trian Believes Solventum Has Potential to Drive Significant Improvements as a Standalone Company If Solventum Can Restore Performance to Historical Levels, Trian Believes the Company's Shares Could be Worth $140 by Year-End 2027 vs. its $69 Share Price Today Trian Believes the Company Can Further Enhance Value Creation Through Improved Operating Performance, Portfolio Actions and Prudent Capital Allocation NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Trian Fund Management, L.P. ("Trian"), which beneficially owns ~5% of Solventum Corporation (NYSE:SOLV) ("Solventum" or the "Company") and is the Company's largest active shareholder, to

Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker BOSTON, Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Eliza

ST. PAUL, Minn., Nov. 19, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that its executives will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 11:30 a.m. ET in New York, NY. A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com. About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, w

Clarity Precision Grip Attachments are fully cured, pre-loaded and precisely resemble the digital treatment plan after bonding ST. PAUL, Minn., Nov. 14, 2024 /PRNewswire/ -- This month, Solventum (NYSE:SOLV), formerly 3M Health Care, officially launched an anticipated innovation in aligner treatment, 3M™ Clarity™ Precision Grip Attachments. Available exclusively with 3M™ Clarity™ Aligners, Clarity Precision Grip Attachments are designed to solve one of the biggest challenges with aligner treatment – creating durable, accurately shaped, stain resistant attachments. "With the l

Reported sales increased 0.4% to $2.082 billion; organic sales increased 0.3%GAAP Earnings Per Share (EPS) of $0.70; adjusted EPS1 of $1.64Generated $169 million in cash from operations; free cash flow1 of $76 millionRaises full-year 2024 organic sales growth, adjusted EPS and free cash flow guidanceST. PAUL, Minn., Nov. 7, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the third quarter ended September 30, 2024. "We have now delivered consecutive quarters of outperformance against our expectations, and based on these results, we are again rai

ST. PAUL, Minn., Oct. 15, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its third quarter 2024 financial results on Thursday, November 7, 2024 after the U.S. financial markets close. The company will also host a conference call that day at 4:30 p.m. Eastern Time to discuss its third quarter financial results and provide an update on its business. The conference call can be accessed via audio webcast at investors.solventum.com or by dialing (800) 715-9871 within the U.S. or +1 (646) 307-1963 for international callers using the conference ID #6342275. A replay of the w

ST. PAUL, Minn., Oct. 14, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV), formerly 3M Health Care, today pledges to use 100% renewable electricity across its worldwide operations by 2030. This move highlights Solventum's commitment to sustainability and the critical role of the healthcare industry in addressing climate change. It also demonstrates how the company is integrating sustainable practices in its facilities and innovating solutions for customers. Since 2021, Solventum has transitioned ten manufacturing sites across the United States, Canada, Germany, Poland and France to

ST. PAUL, Minn., Oct. 10, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that Dr. Ryan Egeland, MD, has been named chief medical officer. Dr. Egeland is responsible for leading Solventum's Global Medical and Clinical Affairs team, amplifying the voice of clinicians and patients. In this role, he will focus on fostering industry collaboration and identifying innovation and market expansion opportunities at the intersection of scientific rigor, clinical need, and commercial practicality. Dr. Egeland will report to Chris Barry, executive vice president and group presi

New V.A.C.® Peel and Place Dressing makes negative pressure wound therapy more accessible, less painful ST. PAUL, Minn., Sept. 10, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) today announced the launch of the V.A.C.® Peel and Place Dressing, an integrated dressing and drape that can be applied in less than two minutesi and worn by patients for up to seven daysii. Traditional dressings for negative pressure wound therapy typically take more than twice as long to apply, require a multi-step process of measuring and cutting separate foam and adhesive components, and may need to be

ST. PAUL, Minn., Aug. 28, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) executives plan to participate in the following investor conferences: 2024 Wells Fargo Healthcare Conference in Everett, MA on Wednesday, September 4, 2024 at 11:00 a.m. ET.Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on Thursday, September 5, 2024 at 11:30 a.m. ET.Live and archived audio webcasts will be available on the company's website at investors.solventum.com.    About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a

Despite Performance Declines Since Spinning Out of 3M, Trian Believes Solventum Has Potential to Drive Significant Improvements as a Standalone Company If Solventum Can Restore Performance to Historical Levels, Trian Believes the Company's Shares Could be Worth $140 by Year-End 2027 vs. its $69 Share Price Today Trian Believes the Company Can Further Enhance Value Creation Through Improved Operating Performance, Portfolio Actions and Prudent Capital Allocation NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Trian Fund Management, L.P. ("Trian"), which beneficially owns ~5% of Solventum Corporation (NYSE:SOLV) ("Solventum" or the "Company") and is the Company's largest active shareholder, to

Reported sales increased 0.4% to $2.082 billion; organic sales increased 0.3%GAAP Earnings Per Share (EPS) of $0.70; adjusted EPS1 of $1.64Generated $169 million in cash from operations; free cash flow1 of $76 millionRaises full-year 2024 organic sales growth, adjusted EPS and free cash flow guidanceST. PAUL, Minn., Nov. 7, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the third quarter ended September 30, 2024. "We have now delivered consecutive quarters of outperformance against our expectations, and based on these results, we are again rai

ST. PAUL, Minn., Oct. 15, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its third quarter 2024 financial results on Thursday, November 7, 2024 after the U.S. financial markets close. The company will also host a conference call that day at 4:30 p.m. Eastern Time to discuss its third quarter financial results and provide an update on its business. The conference call can be accessed via audio webcast at investors.solventum.com or by dialing (800) 715-9871 within the U.S. or +1 (646) 307-1963 for international callers using the conference ID #6342275. A replay of the w

Separation activities and business continuity on trackReported sales increased 0.2% to $2.081 billion; organic sales increased 1.3%GAAP Earnings Per Share (EPS) of $0.51; adjusted EPS1 of $1.56Generated $355 million in cash from operations; free cash flow1 of $297 millionRaises full-year 2024 organic sales growth and adjusted EPS guidanceST. PAUL, Minn., Aug. 8, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results as a stand-alone company for the second quarter ended June 30, 2024. "As we continue to execute a complex transformation, we're encouraged by

ST. PAUL, Minn., July 16, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its second quarter 2024 financial results on Thursday, August 8, 2024 after the U.S. financial markets close. The company will also host a conference call that day at 4:30 p.m. Eastern Time to discuss its second quarter financial results and provide an update on its business. The conference call can be accessed via audio webcast at investors.solventum.com or by dialing (800) 715-9871 within the U.S. or +1 (646) 307-1963 for international callers, using the conference ID 6342275. A replay of the w